Targeting the tumor stroma for cancer therapy
M Xu, T Zhang, R **a, Y Wei, X Wei - Molecular Cancer, 2022 - Springer
Tumors are comprised of both cancer cells and surrounding stromal components. As an
essential part of the tumor microenvironment, the tumor stroma is highly dynamic …
essential part of the tumor microenvironment, the tumor stroma is highly dynamic …
Overcoming therapy resistance in EGFR-mutant lung cancer
Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
M Yuan, LL Huang, JH Chen, J Wu, Q Xu - Signal transduction and …, 2019 - nature.com
Lung cancer is one of the most common cancer in the world. In 2018, there were over 2
million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer …
million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer …
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled …
K Nakagawa, EB Garon, T Seto, M Nishio… - The Lancet …, 2019 - thelancet.com
Background Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an …
H Saito, T Fukuhara, N Furuya, K Watanabe… - The Lancet …, 2019 - thelancet.com
Background Resistance to first-generation or second-generation EGFR tyrosine kinase
inhibitor (TKI) monotherapy develops in almost half of patients with EGFR-positive non-small …
inhibitor (TKI) monotherapy develops in almost half of patients with EGFR-positive non-small …
[HTML][HTML] Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC
The vascular endothelial growth factor (VEGF) pathway has been recognized as a key
mediator of angiogenesis to support tumorigenesis. Multiple therapeutic agents targeting …
mediator of angiogenesis to support tumorigenesis. Multiple therapeutic agents targeting …
Understanding and targeting resistance mechanisms in NSCLC
J Rotow, TG Bivona - Nature Reviews Cancer, 2017 - nature.com
The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …
[HTML][HTML] Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors
Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …
Correction to:“Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
1. In KEYNOTE-189, patients with metastatic non-squamous NSCLC, PS 0-1, without
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …